1. Introduction: Redefining the Struggle Against Severe Asthma
Severe asthma remains a high-stakes clinical challenge, accounting for a disproportionate share of asthma-related morbidity, mortality, and healthcare expenditure. For the clinician, managing these patients requires a shift from broad-spectrum symptom control to a precision-medicine framework that addresses specific underlying endotypes.
To provide a roadmap for this evolving landscape, the European Respiratory Society (ERS) and the American Thoracic Society (ATS) published a landmark update to their clinical guidelines—the first major revision since 2014. This collaboration was necessitated by the rapid emergence of targeted biologics, necessitating a GRADE-assessed synthesis of evidence to guide therapy. Central to this update is the rigorous definition of the patient population in question:
When a diagnosis of asthma is confirmed and comorbidities addressed, severe asthma is defined as “asthma that requires treatment with high dose inhaled corticosteroids […] plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy”.
2. The Biologic Revolution: Targeting Type 2 Inflammation
The "Biologic Revolution" has moved beyond simple eosinophil suppression toward the targeted modulation of Type 2 (T2) cytokines. The ERS/ATS Task Force provides conditional recommendations for the use of monoclonal antibodies in adults with severe uncontrolled eosinophilic asthma.
The following table synthesizes the biological strategies currently recommended for adult populations:
| Drug Name/Class | Primary Benefit | Target Population | Evidence Strength (GRADE) |
|---|---|---|---|
| Mepolizumab (Anti-IL-5) | 50% reduction in exacerbation rates; significant OCS-sparing effects. | Adults with severe uncontrolled eosinophilic phenotype. | Conditional / Low Quality |
| Reslizumab (Anti-IL-5) | 54% reduction in exacerbations; improved asthma control (ACQ-7). | Adults with severe eosinophilic asthma (specifically blood eosinophils $\ge 400 \mu L^{-1}$). | Conditional / Low Quality |
| Benralizumab (Anti-IL-5R$\alpha$) | 42–55% reduction in exacerbations; 75% median OCS dose reduction. | Adults with severe uncontrolled eosinophilic asthma; OCS-dependent. | Conditional / Low Quality |
| Dupilumab (Anti-IL-4/13) | 46–70.5% reduction in exacerbations; substantial OCS-sparing effects. | Adults with severe eosinophilic or corticosteroid-dependent asthma. | Conditional / Low Quality |
The Clinical Logic of IL-4/13 Inhibition
Dupilumab occupies a unique niche in the therapeutic hierarchy. By targeting the IL-4R$\alpha$ subunit, it effectively blocks signaling for both IL-4 and IL-13—two critical drivers of the T2 inflammatory cascade. This mechanism explains why Dupilumab is the only biologic currently suggested for OCS-dependent patients regardless of their baseline blood eosinophil levels. While anti-IL-5 agents target the eosinophil directly, Dupilumab's broader signaling blockade addresses the upstream drivers of steroid resistance.
3. Precision Medicine: Using Biomarkers to Guide Initiation
Selecting a biologic requires more than a "trial and error" approach; it requires the precise application of biomarkers to predict clinical response. The Task Force has identified specific thresholds to optimize patient selection, though clinicians must note these are often based on low-quality, post-hoc evidence.
- Anti-IL-5 Initiation: A blood eosinophil count of $\ge 150 \mu L^{-1}$ is suggested to guide the initiation of anti-IL-5 therapy in adult patients, provided they have a documented history of prior asthma exacerbations. (Conditional Recommendation, Low-Quality Evidence).
- Anti-IgE (Omalizumab) Initiation: To identify adolescents (>12 years) and adults most likely to benefit from omalizumab, the following cut-points are suggested:
- Blood Eosinophils: $\ge 260 \mu L^{-1}$
- FeNO (Fractional exhaled Nitric Oxide): $\ge 19.5$ ppb
- Clinical Warning: These thresholds were determined through post-hoc analyses and have not been prospectively evaluated. Clinicians should apply these cut-offs cautiously, as patients below these levels may still derive benefit.
Clinical Pearl: The Exclusion of Periostin
While serum periostin was initially identified as a promising T2 biomarker, it was omitted from the final recommendations. Periostin levels are not yet standardized for routine clinical use, and in pediatric or adolescent populations, levels are significantly confounded by skeletal growth and puberty, rendering it an unreliable indicator of airway inflammation in younger patients.
4. Beyond Biologics: Tiotropium and the Role of Macrolides
The guidelines also provide clarity on non-biologic add-on therapies, distinguishing between therapies with broad cross-age utility and those requiring adult-specific caution.
- Inhaled Tiotropium: The Task Force issued a Strong Recommendation (Moderate-Quality Evidence) for the addition of Tiotropium in patients whose asthma remains uncontrolled on GINA step 4–5 or NAEPP step 5. This applies to adults, adolescents, and children age >5 years. Tiotropium has demonstrated a consistent ability to improve lung function (FEV1) and increase the time to the first exacerbation requiring systemic steroids.
- Chronic Macrolide Therapy: A trial of chronic macrolides (e.g., Azithromycin) is suggested for persistently symptomatic adults on step 5 therapy to reduce exacerbations, irrespective of their eosinophilic phenotype.
Warning: The Task Force suggests against the use of chronic macrolide treatment in children and adolescents. This is due to a lack of clear efficacy in pediatric cohorts and significant concerns regarding the acceleration of antimicrobial resistance.
5. Implementation Considerations: Cost, Equity, and Feasibility
The transition to biological therapy is often limited by practical barriers. Clinicians must weigh the high cost and local feasibility of these treatments against their clinical benefits.
- Global Equity & Parasitic Infection: In low- and middle-income settings, clinicians must exercise diagnostic caution. Peripheral blood eosinophilia may be driven by parasitic infections rather than Type 2 asthma. Initiating expensive biologics in these patients without ruling out helminthic disease is both clinically and economically unsound.
- The "Treatable Trait" Approach: The guidelines advocate for a shift toward identifying "treatable traits" rather than rigid diagnostic stereotypes. Research suggests that airway eosinophilia should be treated as a primary target regardless of a patient's smoking history or the presence of fixed airflow obstruction—factors that traditionally excluded many patients from biologic clinical trials.
6. Conclusion: The Road Ahead for Severe Asthma Management
The 2020 ERS/ATS guidelines prioritize the reduction of Oral Corticosteroid (OCS) exposure to mitigate long-term systemic morbidity. A critical "forward-looking" observation by the Task Force is the potential for biologics to be used as a single-injection strategy following an acute event. Because the month following an exacerbation is the period of highest relapse risk, biologics may serve to "buy time" and stabilize patients with known adherence issues while social and environmental factors are addressed.
Top 5 Clinical Takeaways
- Embrace the OCS-Sparing Mandate: The primary success metric for new biologics is the reduction or elimination of maintenance systemic corticosteroids.
- Target the $\ge 150 \mu L^{-1}$ Threshold: For Anti-IL-5 initiation, this eosinophil count—coupled with an exacerbation history—is the primary guide for adult patients.
- Tiotropium is a Multigenerational Tool: Unlike many newer agents, Tiotropium carries a Strong Recommendation for patients across the lifespan (age >5 through adulthood).
- Exercise Caution with Anti-IgE Thresholds: Use the $\ge 260 \mu L^{-1}$ eosinophil and $\ge 19.5$ ppb FeNO cut-points cautiously, recognizing they are not yet prospectively validated.
- Dupilumab for the OCS-Dependent: For adults dependent on maintenance OCS, Dupilumab is recommended regardless of eosinophil status due to its unique IL-4/IL-13 signaling blockade.
Looking ahead, we must prioritize the study of pediatric-specific endotypes and long-term safety. As we move away from "one-size-fits-all" protocols, the focus remains on the deployment of standard medications to their maximum benefit before escalating to the "exciting new world" of biological intervention.
7. References and Source Attribution
Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2020; 55: 1900588.